Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 37318 - electrode strap, single use - the portrait spo2 attachment accessory band (portrait aab01) is intended to provide a means to secure the portrait wearable pulse oximetry sensor with portrait sensor battery to the patient?s wrist. the portrait spo2 attachment accessory band is intended for use under the direct supervision of a licensed practitioner, or by personnel trained in proper use of the equipment in a professional healthcare facility.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare iits australia pty ltd - 60723 - medical image management system - this device is intended to display medical images and data from various imaging sources, and from other healthcare information sources. medical images and data can be displayed, communicated, stored, and processed. typical users of this system are authorized healthcare professionals. the device is intended to assist in the viewing, analysis, diagnostic interpretation, and sharing of images and other information.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; trometamol; sodium hydroxide; water for injections; sodium chloride; calcium chloride dihydrate; sodium calcium edetate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: sodium chloride; trometamol; sodium calcium edetate; hydrochloric acid; sodium hydroxide; water for injections; calcium chloride dihydrate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: calcium chloride dihydrate; trometamol; sodium chloride; sodium hydroxide; sodium calcium edetate; hydrochloric acid; water for injections - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; hydrochloric acid; sodium chloride; sodium hydroxide; calcium chloride dihydrate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.